Augmedix

Augmedix, Inc. engages in the development of software that converts natural clinician-patient conversations into medical documentation. It offers live support including referrals, orders, and reminders that allow clinicians to focus on patient care. The company was founded by Ian Shakil in 2012 and is headquartered in San Francisco, CA.

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Augmedix reports record Q4 earnings, eyes growth in healthcare tech

Augmedix demonstrated robust performance in Q4 2022 with strong revenue growth and bookings.
The company's strategic focus on product development and expansion into new markets bodes well for future growth.
While facing challenges in expenses and competition, Augmedix's opportunities for growth are significant.
Investors can be optimistic about Augmedix's outlook given its solid financial performance and growth prospects.

Augmedix reports robust Q1 growth, eyes profitability amid rising expenses

Augmedix demonstrated strong revenue growth, customer retention, and cost management in Q1 2023.
While facing challenges such as increasing expenses and cash outflows, the company remains focused on achieving profitability.
With a solid financial position and growth opportunities ahead, Augmedix is poised for continued success in the healthcare technology sector.

Augmedix reports robust Q2 growth, raises revenue guidance for 2023

Augmedix's Q2 performance reflects strong revenue growth, margin expansion, and strategic partnerships driving market positioning. While facing challenges in managing expenses and achieving profitability, the company remains optimistic about its growth trajectory. Augmedix's focus on innovation and capacity expansion positions it well to capitalize on opportunities for sustained revenue growth and market competitiveness.

Augmedix reports strong Q3 earnings, introduces AI app for clinicians

Augmedix demonstrated robust financial growth and operational improvements in Q3 2023, positioning itself for continued success.
The company's innovative product offerings and strategic partnerships underscore its commitment to driving healthcare efficiency.
While facing challenges such as product adoption ramp-up and regulatory compliance, Augmedix remains focused on growth and innovation.

Augmedix reports robust Q4 earnings, eyes growth in healthcare tech

Augmedix's strong financial performance in Q4 2023 reflects revenue growth, improved EBITDA, and strategic cost management, positioning the company for future success.
Diverse product offerings, positive partnerships, and efficient capital deployment are key strengths driving Augmedix's growth trajectory and market competitiveness.
While facing profitability challenges and the need for revenue diversification, Augmedix has significant opportunities in the expanding healthcare technology market and strong market demand for its products.

Augmedix reports robust Q1 growth, eyes AI-first SaaS transition

Augmedix's Q1 performance reflects strong revenue growth and strategic product launches, despite challenges in revenue outlook and increased expenses.
The company's focus on transitioning to an AI-first SaaS model and leveraging partnerships like HCA Healthcare positions it for future growth.
Optimism about clinical adoption and a commitment to reaching cash flow breakeven by 2025 highlight Augmedix's long-term strategic vision.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

SAN FRANCISCO, Oct. 02, 2024 (GLOBE NEWSWIRE) -- Commure, a healthcare technology company, announced today that it has completed the acquisition of Augmedix. Augmedix will now operate as a wholly-owned subsidiary of Commure.

Commure Completes Merger with Augmedix

Beamr Imaging Ltd

Nerdy

Perfect Corp

Phunware Inc

Richtech Robotics Inc

If you're considering an investment in penny stocks, you should consider looking into those in markets with a lot of room for innovation.

7 AI Penny Stocks to Watch in October

NEW YORK , Sept. 6, 2024 /PRNewswire/ -- Monteverde & Associates PC (the "M&A Class Action Firm"), has recovered money for shareholders and is recognized as a Top 50 Firm in the 2018-2022 ISS Securities Class Action Services Report.

STOCKHOLDER ALERT: The M&A Class Action Firm Investigates the Merger and Looming Vote on September 27, 2024, of Augmedix, Inc. - AUGX

Augmedix, Inc. (AUGX) came out with a quarterly loss of $0.16 per share versus the Zacks Consensus Estimate of a loss of $0.12. This compares to loss of $0.12 per share a year ago.

Augmedix, Inc. (AUGX) Reports Q2 Loss, Lags Revenue Estimates

SAN FRANCISCO, Aug. 12, 2024 (GLOBE NEWSWIRE) -- Augmedix (Nasdaq: AUGX), a leader in ambient AI medical documentation and data solutions, today reported financial results for the three months ended June 30, 2024.

Augmedix Delivers 27% Revenue Growth for Second Quarter of 2024

NEW YORK, July 30, 2024 (GLOBE NEWSWIRE) -- Monteverde & Associates PC (the “M&A Class Action Firm”), has recovered money for shareholders and is recognized as a Top 50 Firm in the 2018-2022 ISS Securities Class Action Services Report. We are headquartered at the Empire State Building in New York City and are investigating Augmedix , Inc . ( Nasdaq : AUGX ) , relating to its proposed merger with Commure, Inc. Under the terms of the agreement, Augmedix stock will be converted into the right to receive $2.35 in cash per share.

STOCKHOLDER ALERT: The M&A Class Action Firm Investigates the Merger of Augmedix, Inc. – AUGX

Amid a sea of red in today's stock market, AI medical documentation and data solutions company Augmedix (NASDAQ: AUGX ) is certainly among the standout winners. Shares of AUGX stock have skyrocketed 150% in afternoon trading on a rather substantial announcement.

Why Is Augmedix (AUGX) Stock Up 150% Today?

NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Augmedix, Inc. (NASDAQ: AUGX) to Commure, Inc. for $2.35 per share in cash is fair to Augmedix shareholders. Halper Sadeh encourages Augmedix shareholders to click here to learn more about their legal rights and options or contact Daniel Sadeh or Zachary Halper at (212) 763-0060 or sadeh@halpersadeh.com or zhalper@halpersadeh.com. The investigation concerns whether Augmedix and its boa.

AUGX Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Augmedix, Inc. Is Fair to Shareholders

MILWAUKEE , July 19, 2024 /PRNewswire/ -- Ademi LLP is investigating Augmedix (Nasdaq: AUGX) for possible breaches of fiduciary duty and other violations of law in its transaction with Commure. Click here to learn how to join our investigation https://www.ademilaw.com/case/augmedix-inc or call Guri Ademi toll-free at 866-264-3995.

Shareholder Alert: Ademi LLP investigates whether Augmedix, Inc. has obtained a Fair Price for its Public Shareholders

Combination to Strengthen Ability to Deliver Frontier Ambient AI Solutions; Augmedix Stockholders to Receive $2.35 Per Share in All-Cash Acquisition by Commure Combination to Strengthen Ability to Deliver Frontier Ambient AI Solutions; Augmedix Stockholders to Receive $2.35 Per Share in All-Cash Acquisition by Commure

Augmedix to Join Forces with Commure

Emergency Services Inc. introduces Augmedix Go ED to central Ohio emergency departments to automate medical documentation Emergency Services Inc. introduces Augmedix Go ED to central Ohio emergency departments to automate medical documentation

Emergency Services Inc. Partners with Augmedix to Introduce Generative AI Solution That Relieves Clinician Burnout in Emergency Departments

Management Provides Update in Advance of William Blair Annual Growth Stock Conference Appearance Management Provides Update in Advance of William Blair Annual Growth Stock Conference Appearance

Augmedix Reiterates Second Quarter and Full Year 2024 Outlook

Unique combination of clinical experience and AI technological expertise will aid Augmedix in solving clinicians' challenges with advanced ambient medical documentation solutions Unique combination of clinical experience and AI technological expertise will aid Augmedix in solving clinicians' challenges with advanced ambient medical documentation solutions

Augmedix Appoints Alex Stinard, M.D., as Chief Clinical AI Officer

Augmedix (NASDAQ: AUGX ) stock is sliding lower on Tuesday after the medical documentation solutions company released its Q1 2024 earnings report. The bad news for AUGX investors comes from its outlook update.

Why Is Augmedix (AUGX) Stock Down 41% Today?

Augmedix, Inc. (NASDAQ:AUGX ) Q1 2024 Earnings Conference Call May 13, 2024 4:30 PM ET Company Participants Matt Chesler - IR Manny Krakaris - CEO Paul Ginocchio - CFO Conference Call Participants Ryan Daniels - William Blair Elizabeth Anderson - Evercore ISI Aaron Wukmir - Lake Street Capital Markets Yuan Zhi - B. Riley Securities Allen Klee - Maxim Group Bill Sutherland - The Benchmark Company Operator Ladies and gentlemen, greetings and welcome to the Augmedix, Inc. First Quarter 2024 Earnings Conference Call.

Augmedix, Inc. (AUGX) Q1 2024 Earnings Call Transcript

SAN FRANCISCO, May 13, 2024 (GLOBE NEWSWIRE) -- Augmedix (Nasdaq: AUGX), a leader in ambient AI medical documentation and data solutions, today reported financial results for the three months ended March 31, 2024.

Augmedix Delivers 40% Revenue Growth for First Quarter of 2024

SAN FRANCISCO, May 03, 2024 (GLOBE NEWSWIRE) -- Augmedix, Inc. (Nasdaq: AUGX), a leader in ambient AI medical documentation and data solutions, today announced that its management team will participate in the following four investor conferences in May and June 2024.

Augmedix to Participate in Upcoming Investor Conferences in May and June 2024

Following incubation with HCA Healthcare EDs, Augmedix announces the general availability of Augmedix Go in emergency departments Following incubation with HCA Healthcare EDs, Augmedix announces the general availability of Augmedix Go in emergency departments

Augmedix Launches Industry's First Fully-Automated, GenAI-Powered, Medical Documentation Product for Emergency Departments

Lucid Diagnostics

Stereotaxis Inc

Let's just get something straight off the bat – penny stocks to rebound are risky. They're incredibly treacherous in terms of both short-term downside and longer-term damage to your portfolio.

3 Penny Stocks That Could Make a Big Comeback by the End of Q2

SAN FRANCISCO and ORLANDO, Fla., April 09, 2024 (GLOBE NEWSWIRE) -- In a significant move to streamline healthcare workflows and allow clinicians to focus on patient care, Augmedix (Nasdaq: AUGX), a leader in ambient AI medical documentation and data solutions, announced today that it has integrated with Andor Health , an AI-first cloud-based communication and collaboration platform for virtual care.

Augmedix Integrates with Andor Health to Revolutionize Ambient Clinical Documentation for Ambulatory Virtual Care

The partnership enables Augmedix to accelerate scaling efforts for digital health solutions and integrations that work seamlessly at the point of care The partnership enables Augmedix to accelerate scaling efforts for digital health solutions and integrations that work seamlessly at the point of care

Augmedix and SADA Forge Partnership to Scale Ambient Documentation and Structured Data Products to Health Systems Nationwide

Augmedix is a company developing an AI-driven medical documentation platform for hospitals and physicians. The company's stock performance has been underwhelming since going public, with a current all-time return of -15%. The company's financials show steady growth but continued losses, and there are concerns about profitability and cash flow generation, making risk-reward unattractive for now.

Augmedix: Secular AI Tailwinds, But Still Unattractive Risk-Reward

Augmedix, Inc. (AUGX) Q4 2023 Earnings Call Transcript

SAN FRANCISCO, March 18, 2024 (GLOBE NEWSWIRE) -- Augmedix (Nasdaq: AUGX), a leader in ambient AI medical documentation and data solutions, today reported financial results for the three and 12 months ended December 31, 2023.

Augmedix Delivers 45% Revenue Growth and Expanded Gross Margins for Fourth Quarter of 2023

New Data Shows Clinicians Save Up to 1 Hour or More per Day Using Augmedix Go New Data Shows Clinicians Save Up to 1 Hour or More per Day Using Augmedix Go

News for Augmedix Stock (AUGX)